

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2015

---

SEMLER SCIENTIFIC, INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation)

001-36305  
(Commission File Number)

26-1367393  
(IRS Employer Identification No.)

2330 NW Everett St.  
Portland, Oregon  
(Address of principal executive offices)

97210  
(Zip Code)

Registrant's telephone number, including area code: (877) 774-4211

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 2.02 Results of Operations and Financial Condition.**

On October 30, 2015, Semler Scientific, Inc. issued a press release announcing its financial results for the third quarter of 2015. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

*The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.*

**Item 9.01 Financial Statements and Exhibits.**

*The information contained in this Item 9.01 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.*

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of Semler Scientific, Inc., dated October 30, 2015

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEMLER SCIENTIFIC, INC.**

By: /s/ Douglas Murphy-Chutorian, M.D.  
Name: Douglas Murphy Chutorian, M.D.  
Title: Chief Executive Officer

Date: October 30, 2015

---

## Semler Reports Third Quarter 2015 Financial Results

### *Year Over Year Growth of 74%; Quarterly Growth of 20%*

**PORTLAND, Ore.** – October 30, 2015 – Semler Scientific, Inc. (Nasdaq: SMLR; “Semler”), a company that provides diagnostic and testing services to healthcare insurers and physician groups, today reported financial results for the third quarter ended September 30, 2015.

“In the third quarter of 2015, Semler reported continued progress with year over year revenue growth of 74% and quarter over quarter revenue growth of 20%” said Doug Murphy-Chutorian, M.D., chief executive officer of Semler. “During this period, we booked new orders expected to generate additional revenues in the fourth quarter from WellChec™, our new multi-test service offering, and we launched QuantaFlo™, our next generation testing system for vascular disease.”

### FINANCIAL RESULTS

In the three months ended September 30, 2015, compared to the corresponding period of 2014, Semler had:

- Revenue of \$1,562,000, an increase of \$665,000, or 74%, compared to \$897,000
- Cost of revenue of \$385,000, an increase of \$207,000, or 117%, compared to \$178,000
- Total operating expenses, which include cost of revenue, of \$3,114,000, an increase of \$850,000, or 37%, compared to \$2,264,000
- Net loss of \$1,580,000, or \$0.32 per share, an increase of \$114,000, or 8%, compared to a net loss of \$1,466,000, or \$0.31 per share

In the nine months ended September 30, 2015, compared to the corresponding period of 2014, Semler had:

- Revenue of \$4,067,000, an increase of \$1,487,000, or 58%, compared to \$2,580,000
- Cost of revenue of \$887,000, an increase of \$383,000, or 76%, from \$504,000
- Total operating expenses, which include cost of revenue, of \$8,281,000, an increase of \$2,536,000, or 44%, compared to \$5,745,000
- Net loss of \$4,293,000, or \$0.87 per share, an increase of \$978,000, or 30%, compared to a net loss of \$3,315,000, or \$0.85 per share
- During the nine months of 2015, we issued and sold an aggregate of 260,500 shares of our common stock for an aggregate cash purchase price of \$999,100

In the three months ended September 30, 2015, compared to the three months ended June 30, 2015, Semler had:

- Revenue of \$1,562,000, an increase of \$259,000, or 20%, compared to \$1,303,000
  - Cost of revenue of \$385,000, an increase of \$141,000, or 58%, from \$244,000
-

- Total operating expenses, which include cost of revenue, of \$3,114,000, an increase of \$498,000, or 19%, compared to \$2,616,000
- Net loss of \$1,580,000, or \$0.32 per share, an increase of \$239,000, or 18%, compared to a net loss of \$1,341,000, or \$0.27 per share
- Unrestricted cash of \$1,925,000, a decrease of \$415,000 compared to \$2,340,000

### **Third Quarter 2015 Highlights**

The third quarter of 2015 for Semler resulted in continued revenue expansion. Other highlights included:

- The launch of QuantaFlo™, the next generation product for testing for vascular disease. Semler believes that customers will be attracted to its enhanced performance features and expanded marketing labeling.
- The initiation of our second contract this year for WellChec™, our new multi-test service offering.
- Obtaining several new orders for WellChec™, which if successfully fulfilled would significantly impact revenue in the fourth quarter of 2015.

"We had our best quarter in dollar terms of sequential quarterly growth and added new larger clients contracting for our WellChec™ service," said Dr. Murphy-Chutorian. "We are furthering our goal to aid physicians and insurance plans to evaluate their patients earlier and more comprehensibly, which may in turn lead to more prevention and lower healthcare costs," he added.

### **Notice of Conference Call**

Semler will host a conference call at 11 a.m. EST, Friday, October 30, 2015. The call will address third quarter results and will provide a business update on Semler's market outlook and strategies for the near-term future.

The conference call may be accessed by dialing (877) 359-9508 for domestic callers and (224) 357-2393 for international callers. Please specify to the operator that you would like to join the "Semler Third Quarter 2015 Financial Results Call, conference ID#: 57014373." The conference call will be archived on Semler's website at [www.semilerscientific.com](http://www.semilerscientific.com).

---

**Semler Scientific, Inc.**  
**Unaudited Condensed Statements of Operations**  
(In thousands, except share and per share amounts)

	<u>For the three months ended September 30</u>		<u>For the nine months ended September 30</u>	
	2015	2014	2015	2014
Revenue	\$ 1,562	897	\$ 4,067	2,580
Operating expenses:				
Cost of revenue	385	178	887	504
Engineering and product development	268	262	983	906
Sales and marketing	1,314	1,040	3,809	2,514
General and administrative	1,147	784	2,602	1,821
Total operating expenses	<u>3,114</u>	<u>2,264</u>	<u>8,281</u>	<u>5,745</u>
Loss from operations	<u>(1,552)</u>	<u>(1,367)</u>	<u>(4,214)</u>	<u>(3,165)</u>
Other expense:	<u>(28)</u>	<u>(99)</u>	<u>(79)</u>	<u>(150)</u>
Net loss	<u>\$ (1,580)</u>	<u>\$ (1,466)</u>	<u>\$ (4,293)</u>	<u>\$ (3,315)</u>
Net loss per share, basic and diluted	<u>\$ (0.32)</u>	<u>\$ (0.31)</u>	<u>\$ (0.87)</u>	<u>\$ (0.85)</u>
Weighted average number of shares used in computing basic and diluted loss per share	<u>4,983,198</u>	<u>4,708,162</u>	<u>4,909,354</u>	<u>3,900,746</u>

**Semler Scientific, Inc.**  
**Unaudited Condensed Balance Sheet**  
(In thousands of U.S. Dollars)

	<b>As of</b> <b>September 30, 2015</b>	<b>As of</b> <b>December 31, 2014</b>
Cash and restricted cash	\$ 1,925	\$ 6,256
Other current assets	529	490
Noncurrent assets	<u>1,066</u>	<u>754</u>
Total assets	<u><u>3,520</u></u>	<u><u>7,500</u></u>
Current liabilities	2,941	4,064
Non-current Liabilities	48	-
Stockholders' equity	<u>531</u>	<u>3,436</u>
Total liabilities and stockholders' equity	<u><u>\$ 3,520</u></u>	<u><u>\$ 7,500</u></u>

---

## **About Semler Scientific, Inc.:**

Semler Scientific, Inc., is a company that provides diagnostic and testing services to healthcare insurers and physician groups. Our mission is to develop, manufacture and market innovative proprietary products and services that assist healthcare providers in evaluating and treating chronic diseases. Our first patented and U.S. Food and Drug Administration, or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. In March 2015 we received FDA 510(k) clearance for the next generation version of this product named QuantaFlo™, which was commercially launched in August 2015. In April 2015, we launched our multi-test service offering, WellChec™, to more comprehensively evaluate patients for chronic disease. Additional information about Semler can be found at [semlerscientific.com](http://semlerscientific.com).

## **Forward-Looking Statements**

This press release contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words “may,” “will,” “expect,” “anticipate,” “estimate,” “project,” “would,” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding the WellChec™ platform and its impact on revenue growth, as well the effects of Semler Scientific’s products and services on prevention and healthcare costs. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific’s actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will continue to lease its vascular disease testing products or adopt WellChec™, along with those statements detailed in Semler Scientific’s SEC filings, and involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

## **CONTACT:**

Susan A. Noonan  
S.A. Noonan Communications  
[susan@sanoonan.com](mailto:susan@sanoonan.com)  
212 966 3650

**SOURCE:** Semler Scientific, Inc.

#####

---